| Cover | Oct. 01, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Oct. 01, 2024 |
| Entity File Number | 001-36268 |
| Entity Registrant Name | TNF Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001321834 |
| Entity Tax Identification Number | 22-2983783 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 855 N. Wolfe Street |
| Entity Address, Address Line Two | Suite 623 |
| Entity Address, City or Town | Baltimore |
| Entity Address, State or Province | MD |
| Entity Address, Postal Zip Code | 21205 |
| City Area Code | (856) |
| Local Phone Number | 848-8698 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, par value $0.001 per share |
| Trading Symbol | TNFA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
